{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:11:34Z","timestamp":1778155894726,"version":"3.51.4"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JPGN rep."],"published-print":{"date-parts":[[2026,5]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n Upadacitinib, a second\u2010generation Janus kinase (JAK) inhibitor, is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) in adults. Its efficacy in pediatric patients remains unclear, though early reports suggest benefits in refractory inflammatory bowel disease (IBD). However, data indicate potential relapse after dose reduction. This study evaluates upadacitinib's sustained efficacy in pediatric IBD, particularly when transitioning from induction to maintenance dosing.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a case series of 16 pediatric patients (mean age 16.1 years) treated with upadacitinib for refractory IBD between 2023 and 2024. Treatment responses were analyzed in 8 patients who completed induction (45\u2009mg daily) and transitioned to maintenance dosing (30 or 15\u2009mg daily based on provider preference). Relapse rates and responses to dose adjustments were assessed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among the 16 patients, 8 had UC, 7 had CD, and 1 had IBD\u2010unclassified. Seven (43.8%; 95% confidence interval [CI], 19.4%\u201368.1%) lost response after transitioning to maintenance, with a median time to relapse of 81.5 days. Of these, 6 (85.7%; 95% CI, 42%\u201399%) regained response after increasing the dose back to induction dosing.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Our findings suggest that pediatric patients may require longer induction, higher maintenance doses, or individualized dosing due to pharmacokinetics. Given the high relapse rate in our small cohort, close monitoring and tailored treatment strategies are essential.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/jpr3.70157","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:07:52Z","timestamp":1772996872000},"page":"296-300","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of upadacitinib induction for pediatric inflammatory bowel disease"],"prefix":"10.1002","volume":"7","author":[{"given":"Evan","family":"Greenhall","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology Phoenix Children's Hospital Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Gautam","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine\u2010 Phoenix Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Prieto\u2010Jimenez","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology Phoenix Children's Hospital Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hilow","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology Phoenix Children's Hospital Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology Phoenix Children's Hospital Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-871X","authenticated-orcid":false,"given":"Brad","family":"Pasternak","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology Phoenix Children's Hospital Phoenix Arizona USA"},{"name":"University of Arizona College of Medicine\u2010 Phoenix Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020250"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad048"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac247.118"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpr3.12067"},{"issue":"11","key":"e_1_2_7_8_1","article-title":"Single\u2010center experience with upadacitinib for adolescents with refractory inflammatory bowel disease","volume":"30","author":"Spencer EA","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"e_1_2_7_9_1","article-title":"P494 efficacy and safety of upadacitinib in moderate to severe paediatric Crohn's disease and ulcerative colitis in a tertiary paediatric IBD (PIBD) centre \u2013 a case series","volume":"18","author":"Kontaki E","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"1","key":"e_1_2_7_10_1","article-title":"P590 use of upadacitinib in refractory paediatric inflammatory bowel disease: a single\u2010center cohort study","volume":"18","author":"Potapov A","year":"2024","journal-title":"J Crohns Colitis"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1180750"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.661536"},{"key":"e_1_2_7_14_1","article-title":"Current role of monoclonal antibody therapy in pediatric IBD: a special focus on therapeutic drug monitoring and treat\u2010to\u2010target strategies","volume":"10","author":"Cla\u00dfen M","year":"2023","journal-title":"Children (Basel, Switzerland)"}],"container-title":["JPGN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpr3.70157","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpr3.70157","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpr3.70157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:31:06Z","timestamp":1778153466000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpr3.70157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/jpr3.70157"],"URL":"https:\/\/doi.org\/10.1002\/jpr3.70157","archive":["Portico"],"relation":{},"ISSN":["2691-171X","2691-171X"],"issn-type":[{"value":"2691-171X","type":"print"},{"value":"2691-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"2025-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}